Skip to main content

Table 2 List of definitions and derived variables used in the study

From: Impact of next-generation hormonal agents on treatment patterns among patients with metastatic hormone-sensitive prostate cancer: a real-world study from the United States, five European countries and Japan

Initial mHSPC treatment The first treatment that a patient received in the mHSPC setting
NHA drugs abiraterone, enzalutamide, apalutamide, darolutamide
Chemotherapy drugs cabazitaxel, docetaxel, mitoxantrone, cisplatin, paclitaxel, carboplatin, etoposide, estramustine, ifosfamide
ADT drugs degarelix, goserelin, leuprorelin, triptorelin, histrelin, bicalutamide, flutamide, nilutamide, ketoconazole, chlormadinone, cyproterone, buserelin
Immunotherapy drugs sipuleucel-T, pembrolizumab
Radiotherapy drugs radium-223, strontium 89
Corticosteroid drugs prednisone, prednisolone, methylprednisolone, hydrocortisone, dexamethasone, betamethasone
Other drugs diethylstilbestrol, padeliporfin, peplomycin sulfate, any other drug therapies not previously specified
NHA (± ADT) Patients who received NHA (± ADT)
Chemotherapy (± ADT) Patients who received chemotherapy (± ADT)
ADT alone Patients who received ADT alone
Other combination including NHA Patients who received any NHA drugs (not as a NHA (± ADT))
Chemotherapy combination Patient who received a chemotherapy drug (not as a chemotherapy (± ADT)) in their initial mHSPC treatment. This does not include patients who received an NHA (± ADT) or NHA in combination
Any other combination Patients who received a treatment not captured in the NHA (± ADT), chemotherapy (± ADT), ADT alone, other combination including NHA or chemotherapy combination treatment groups
Any NHA Patients who received a NHA drug as either (± ADT) or in combination (± ADT)
No NHA Patients who did not receive a NHA drug as either (± ADT) or in combination (± ADT)
High-risk disease Patients with two of the following: Gleason score of 8 + , presence of visceral metastases, or 3 + bone lesions
Low-risk disease Patients with ≤ 1 of the following: Gleason score of 8 + , presence of visceral metastases, or 3 + bone lesions
High disease volume Patients with either of the following: presence of visceral metastases, or 4 + bone lesions with ≥ 1 beyond the vertebral bodies/pelvis
Low disease volume Patients with neither of the following: presence of visceral metastases, nor 4 + bone lesions with ≥ 1 beyond the vertebral bodies/pelvis
  1. ADT androgen deprivation therapy, mHSPC metastatic hormone-sensitive prostate cancer, NHA novel hormonal agent